Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study
- PMID: 15659459
- DOI: 10.1093/ije/dyh339
Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study
Abstract
Background: Studies of chronic hepatitis B virus (HBV) infection in endemic populations have rarely documented causes of mortality other than liver disease and hepatocellular carcinoma (HCC).
Methods: We analysed all-cause mortality related to HBV infection, focusing on the deaths not related to liver disease in a prospective cohort of adults living in Haimen City, China, who were followed from 1992 to 2002. Death certificate data from 4590 deaths among 83 794 individuals were analysed. At cohort entry, 15.0% of the 58 454 male subjects and 10.7% of 25 340 female subjects were hepatitis B surface antigen positive [HbsAg(+)]. HCC and chronic liver disease were the major causes of death in both men and women in this population. The analysis focused on non-liver causes of death.
Results: When liver-related causes of death were excluded, there was still a significantly higher age-adjusted death rate among HBsAg(+) individuals. The relative risks (RRs) and 95% confidence intervals (CIs) for all non-liver deaths among HBsAg(+) subjects were 1.2 (1.1-1.3) in men and 1.4 (1.1-1.7) in women. Non-liver causes were further subdivided into cancer and non-cancer groups. For all non-liver cancers, the RR was 1.2 (1.0-1.4) for males and 1.7 (1.2-2.3) for females. Non-liver, non-cancer deaths had RRs of 1.2 (1.1-1.4) and 1.2 (0.9-1.6) in males and females, respectively.
Conclusions: HBV-infected individuals may be at increased mortality risk from non-liver causes. Possible reasons include a direct effect of HBV infection, changes in the host immune system as a cause or effect of chronic infection, and behavioural factors associated with HBV infection. Further studies are needed to confirm this finding.
Similar articles
-
Risk and predictors of mortality associated with chronic hepatitis B infection.Clin Gastroenterol Hepatol. 2007 Aug;5(8):921-31. doi: 10.1016/j.cgh.2007.06.015. Clin Gastroenterol Hepatol. 2007. PMID: 17678844
-
Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences.Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):369-76. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 11927497
-
Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.J Natl Cancer Inst. 2009 Jul 15;101(14):1019-27. doi: 10.1093/jnci/djp146. Epub 2009 Jun 17. J Natl Cancer Inst. 2009. PMID: 19535774
-
Diagnosis of hepatitis B virus infection through serological and virological markers.Expert Rev Gastroenterol Hepatol. 2008 Aug;2(4):553-62. doi: 10.1586/17474124.2.4.553. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19072403 Review.
-
Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden.J Viral Hepat. 2009 Jul;16(7):453-63. doi: 10.1111/j.1365-2893.2009.01117.x. Epub 2009 Mar 17. J Viral Hepat. 2009. PMID: 19302335 Review.
Cited by
-
Are physicians following guidelines? A survey of Hepatitis B management strategies.Hepatol Int. 2013 Jun;7(2):451-9. doi: 10.1007/s12072-012-9399-7. Epub 2012 Oct 6. Hepatol Int. 2013. PMID: 26201777
-
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop.Clin Mol Hepatol. 2020 Oct;26(4):411-429. doi: 10.3350/cmh.2020.0049. Epub 2020 Aug 28. Clin Mol Hepatol. 2020. PMID: 32854458 Free PMC article. Review.
-
Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand.Hepatol Int. 2009 Sep;3(3):453-60. doi: 10.1007/s12072-009-9139-9. Epub 2009 Jun 24. Hepatol Int. 2009. PMID: 19669246 Free PMC article.
-
Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures.J Epidemiol. 2011;21(6):401-16. doi: 10.2188/jea.je20100190. Epub 2011 Oct 22. J Epidemiol. 2011. PMID: 22041528 Free PMC article. Review.
-
Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients.Hepatol Int. 2014 Jan;8(1):72-82. doi: 10.1007/s12072-013-9488-2. Epub 2013 Nov 28. Hepatol Int. 2014. PMID: 26202408
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources